Showing results (61-70 of 91) with videos related to
Sort By:
Pageof 10
Frontiers in Immunology|January 30, 2019
Maturing Human CD127+ CCR7+ PDL1+ Dendritic Cells Express AIRE in the Absence of Tissue Restricted AntigensJoannah R Fergusson, Michael D Morgan, Melanie Bruchard, et al.Nature Immunology|April 26, 2016
IL-1β, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungsSuzanne M Bal, Jochem H Bernink, Maho Nagasawa, et al.Journal for Immunotherapy of Cancer|June 9, 2021
Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacyJulie Niogret, Hélène Berger, Cédric Rebe, et al.Immunity|March 13, 2012
Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expressionFanny Chalmin, Grégoire Mignot, Mélanie Bruchard, et al.The Lancet. Oncology|November 7, 2025
Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trialStefano Kim, Jihane Boustani, Soledad Iseas, et al.Cancer Chemotherapy and Pharmacology|May 15, 2014
Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancerMarine Jary, Francois Ghiringhelli, Marion Jacquin, et al.The EMBO Journal|April 20, 2019
Cancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein TRF2Julien Cherfils-Vicini, Charlene Iltis, Ludovic Cervera, et al.Signal Transduction and Targeted Therapy|January 17, 2025
Safety and efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trialMarion Thibaudin, Nicolas Roussot, Chloé Burlot, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2018
Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9)Thomas Aparicio, Francois Ghiringhelli, Valérie Boige, et al.Frontiers in Oncology|September 19, 2022
Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinomaStefano Kim, Jihane Boustani, Dewi Vernerey, et al.Pageof 10